Astellas Pharma Inc., Annual General Meeting, Jun 19, 2026 Apr 27
Astellas Pharma Inc. And Pfizer Inc. Receive U.S. FDA Priority Review For PADCEV And Keytruda As Perioperative Treatment For Muscle-Invasive Bladder Cancer Apr 20
Astellas Pharma Inc. to Report Fiscal Year 2026 Results on Apr 27, 2026 Apr 04
Astellas Pharma Inc. and Hovon Foundation Confirm Phase 3 Study Results for Xospata (Gilteritinib) in Newly Diagnosed FLT3m+ AML Mar 10
Pfizer Inc. and Astellas Pharma Inc. Announce Positive Results from the Phase 3 EV-304 Clinical Trial Feb 28
Astellas Pharma Inc. Reaches Settlement Agreements with Lupin and Zydus in Myrbetriq Patent Litigation Feb 12
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for Fiscal Year Ending March 31, 2026 Feb 05
Astellas Pharma Inc. to Report Q3, 2026 Results on Feb 04, 2026 Jan 10
Astellas Pharma Inc. and Pfizer Inc. Announces Positive Topline Results from an Interim Analysis of the Phase 3 EV-304 Clinical Trial Dec 17
U.S. FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer Nov 22
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for Fiscal Year Ending March 31, 2026 Oct 30
Astellas Pharma Inc. Confirms Phase 2 GLEAM Trial Did Not Meet Primary Endpoint of Overall Survival in Patients with Metastatic Pancreatic Cancer Oct 14
Astellas Pharma Inc. to Report Q2, 2026 Results on Oct 30, 2025 Oct 08
Vyloy® (Zolbetuximab) in Combination with Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer Is Now Funded in Both Ontario and Quebec Oct 02
Astellas Pharma Inc. to Present Pioneering Advances Across Its Portfolio and Pipeline At Esmo 2025 Oct 01
Astellas Pharma Inc. Announces Resignation of Nick Eshkenazi, Current Chief Digital & Transformation Officer, Effective September 30, 2025 Sep 30
Astellas Pharma Inc. Announces Japanese Ministry of Health, Labor and Welfare Grants Conditional Approval of IZERVAY for Suppression of Geographic Atrophy Growth in Atrophic Age-Related Macular Degeneration Sep 19
PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery Aug 12
Astellas Pharma Inc. to Report Q1, 2026 Results on Jul 30, 2025 Jul 11
Pfizer Inc. and Astellas Pharma Inc. Announce Positive Topline Results from the Overall Survival (OS) Analysis from the Phase 3 EMBARK Study Evaluating XTANDI Jul 10
Astellas Pharma Canada, Inc. Announces That XTANDI®? (enzalutamide) Now Funded in Ontario for All Approved Prostate Cancer Indications Jun 27
Astellas Pharma Inc. and Pfizer Inc. Announces Long-Term Overall Survival in Metastatic Hormone-S sensitive Prostate Cancer May 23
Astellas Pharma Inc. Presents New Data That Explores Potential of Its Cancer Therapies At 2025 Asco Annual Meeting May 20
Astellas engages with Farallon May 08
Astellas Pharma Inc., Annual General Meeting, Jun 19, 2025 Apr 25
Astellas Pharma Inc. to Report Fiscal Year 2025 Results on Apr 25, 2025 Apr 03
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy Feb 13
Pfizer Inc. and Astellas Pharma Inc.'s PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer Feb 11
Astellas Pharma Inc. Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan Feb 05
Astellas Pharma Inc. Announces Management Changes, Effective April 1, 2025 Feb 04
Astellas Pharma Inc. Announces China's National Medical Products Administration (Nmpa) Approves Padcev™ in Combination with Keytruda® (Pembrolizumab) for the Treatment of Advanced Bladder Cancer Jan 08
China's National Medical Products Administration Approves Vyloy (Zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Jan 06
Astellas Pharma Inc. to Report Q3, 2025 Results on Feb 04, 2025 Jan 03
Astellas Pharma Inc. Vyloy™ (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej Cancer Oct 19
Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024 Oct 05
Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer Sep 24
Astellas Pharma Inc. to Present VEOZAH (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society Sep 04
European Commission Approves Astellas Pharma Inc.'s PADCEV in Combination with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer Aug 28
Astellas Pharma Inc. Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy Aug 27
Astellas Pharma Inc. Announces Center for Drug Evaluation of China's National Medical Products Administration Approves Padcev (Enfortumab Vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer Aug 20
Astellas Pharma Inc. to Report Q1, 2025 Results on Aug 01, 2024 Jun 29
U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date May 31
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting Apr 25
Astellas Pharma Inc. to Report Fiscal Year 2024 Results on Apr 25, 2024 Apr 03
U.S. FDA Accepts Astellas’ Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy Apr 02
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer Mar 28
Astellas Pharma Inc.'s Vyloy™? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer Mar 27
Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting Mar 22
Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan Mar 05
Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application (sNDA) for PADCEV with KEYTRUDA Feb 16
Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer Jan 31
European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer Jan 27
Astellas Pharma Inc. Provides Update on Zolbetuximab Biologics License Application in U.S Jan 09
Astellas Pharma Inc. to Report Q3, 2024 Results on Feb 05, 2024 Dec 28
Astellas Pharma Inc. Announces EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children Dec 18
Pfizer Inc. and Astellas Pharma Inc. Announce U.S. Food and Drug Administration Approved PADCEV (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) with KEYTRUDA (pembrolizumab, a PD-1 inhibitor) for the Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC) Dec 16
Astellas Pharma Inc. Announces That Its VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause Dec 11
Astellas Pharma US, Inc. Announces FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis Dec 09
Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer Dec 02
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy Nov 30
Pfizer and Astellas' Xtandi Approve by U.S. FDA in Earlier Prostate Cancer Treatment Setting Nov 17
Seagen Inc. and Astellas Pharma Inc. Announces Results from the Phase 3 EV-302 Clinical Trial for PADCEV (Enfortumab Vedotin-Ejfv) in Combination with Keytruda (Pembrolizumab) Versus Chemotherapy Oct 24
Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023 Oct 16
Astellas Receives Positive Chmp Opinion for Veoza (Fezolinetant) Oct 14
Astellas Pharma Inc. to Report Q2, 2024 Results on Nov 01, 2023 Sep 28
Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial Sep 23
Astellas Pharma Inc. Announces Positive 24-Month Topline Results from the Phase 3 GATHER2 Clinical Trial Evaluating the Efficacy and Safety of IZERVAY Sep 19
European Medicines Agency Validates Type II Variation for Astellas' XTANDI (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence Sep 13
Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503). Aug 30
FDA Grants Priority Review for XTANDI in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence Aug 24
Astellas Pharma Inc. Announces European Medicines Agency Accepts for Regulatory Review the Marketing Authorization Application for Avacincaptad Pegol Aug 18
U.S. FDA Accepts Astellas Pharma US, Inc.'s sNDA for CRESEMBA® (isavuconazonium sulfate) in Children Aug 11
Astellas Pharma Inc. Announces the U.S. Food and Drug Administration Approves Izervay (Avacincaptad Pegol Intravitreal Solution) for the Treatment of Geographic At the 12-Month Primary Endpoint Across Two Phase 3 Clinical Trials Aug 09
Astellas Pharma Inc. Revises Consolidated Earnings Guidance on Full Basis for the Full-Year 2023 Aug 03
China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab Aug 01
European Medicines Agency Accepts Astellas' Marketing Authorization Application for Zolbetuximab Jul 14
Astellas Pharma Inc. to Report Q1, 2024 Results on Aug 01, 2023 Jul 12
Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application Jul 06
Astellas Pharma Inc. Announces Positive Topline Results from the Phase 3b DayLIGHT Clinical Trial for Fezolinetant Jun 28
Astellas Pharma Inc. Confirms Unfavorable District Court Decision in Myrbetriq U.S. Patent Trial Jun 12
Astellas Pharma Inc. Announces Submission of New Drug Application to Japan's Ministry of Health, Labour and Welfare for Zolbetuximab Jun 09
Astellas' Veozah Tm (Fezolinetant) Approved by U.S. Fda for Treatment of Vasomotor Symptoms Due to Menopause May 17
Astellas Pharma Inc. Provides Update on Fezolinetant New Drug Application in U.S Feb 20
Astellas Pharma Inc. Announces CEO Changes, Effective April 1, 2023 Feb 06